14 completed, 7 recruiting, 3 terminated, 2 unknown. 28 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 14, Recruiting 7, Terminated 3, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Panitumumab: new trials by email Literature Review of Panitumumab trials Research Report on Panitumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| The Sagittarius Trial Oxaliplatin, Capecitabine, Folinic acid - Colon Cancer Stage II, Colon Cancer Stage III | Phase 3 | Recruiting | IFOM ETS - The AIRC Institute of Molecular Oncology | 700 | 2024-10-22 | 2025-08-29 |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation FOLFIRI Regimen, Sotorasib, Panitumumab - Metastatic Colorectal Cancer | Phase 3 | Recruiting | Amgen | 450 | 2024-07-17 | 2026-09-03 |
| Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer Panitumumab, Irinotecan, 5-fluorouracil - Colorectal Cancer Stage IV | Phase 3 | Recruiting | National Cancer Institute, Naples | 500 | 2024-06-12 | 2024-07-19 |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 408 | 2024-04-10 | 2026-09-24 |
| Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer Cetuximab - Colorectal Neoplasms, Chemotherapy Effect | Phase 3 | Recruiting | City Clinical Oncology Hospital No 1 | 355 | 2024-01-17 | 2024-01-29 |
| Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation Sotorasib, Panitumumab, Trifluridine and Tipiracil - Colorectal Cancer (CRC) | Phase 3 | Completed | Amgen | 160 | 2022-04-19 | 2026-07-22 |
| Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer FOLFOX regimen, Panitumumab, Bevacizumab - Colorectal Cancer | Phase 3 | Active not recruiting | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 419 | 2018-10-15 | 2024-10-21 |
| 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Panitumumab, Oxaliplatin, Leucovorin Calcium - Colorectal Adenocarcinoma, RAS Wild Type | Phase 3 | Terminated | University of Southern California | 4 | 2018-02-27 | 2020-06-11 |
| First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS Panitumumab, Irinotecan, Oxaliplatin - Metastatic Colorectal Cancer | Phase 3 | Completed | Gruppo Oncologico del Nord-Ovest | 435 | 2017-09-13 | 2023-01-05 |
| Lymph Node Ratio and Kras Mutation in R Colon Cancer k ras, Panitumumab - Colon Cancer Stage III | Phase 3 | Completed | Mansoura University | 433 | 2017-03-10 | 2020-04-13 |
| Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver Oxaliplatin intravenous, 5 FU bolus, Folinic acid - Colorectal Neoplasms | Phase 3 | Recruiting | Federation Francophone de Cancerologie Digestive | 348 | 2016-12-01 | 2025-07-09 |
| Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab - Colorectal Cancer | Phase 3 | Completed | Takeda | 823 | 2015-05-29 | 2023-11-01 |
| Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases FOLFOX/ FOLFIRI with bevacizumab, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab - Colorectal Cancer, Liver Metastases | Phase 3 | Completed | Dutch Colorectal Cancer Group | 530 | 2014-07-01 | 2025-02-06 |
| Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab - Colorectal Cancer Metastatic | Phase 3 | Unknown | GERCOR - Multidisciplinary Oncology Cooperative Group | 464 | 2013-10-30 | 2024-03-12 |
| Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer Cisplatin, 5-FU, Panitumumab - Esophageal Squamous Cell Cancer | Phase 3 | Terminated | AIO-Studien-gGmbH | 300 | 2012-05-01 | 2018-03-02 |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer Best Supportive Care (BSC), Panitumumab - Metastatic Colorectal Cancer | Phase 3 | Completed | Amgen | 377 | 2011-11-01 | 2017-03-15 |
| I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Chemotherapy, Panitumumab - Infiltrating Urothelial Carcinoma, KRAS Gene Mutation | Phase 3 | Completed | UNICANCER | 133 | 2010-06-01 | 2021-03-09 |
| ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Cetuximab, Panitumumab - Metastatic Colorectal Cancer | Phase 3 | Completed | Amgen | 1010 | 2010-02-02 | 2022-09-21 |
| Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer panitumumab, cisplatin, 3-dimensional conformal radiation therapy - Head and Neck Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 320 | 2008-12-30 | 2023-08-22 |
Showing 20 of 28. Sign in to see all of them.
Colorectal Neoplasms (19) · Neoplasms (6) · Colonic Neoplasms (5) · Rectal Neoplasms (4) · Neoplasm Metastasis (3) · Head and Neck Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Esophageal Squamous Cell Carcinoma (1) · Pancreatic Neoplasms (1) · Tongue Neoplasms (1)
Amgen (8) · AIO-Studien-gGmbH (1) · City Clinical Oncology Hospital No 1 (1) · Dutch Colorectal Cancer Group (1) · ECOG-ACRIN Cancer Research Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Federation Francophone de Cancerologie Digestive (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · Gruppo Oncologico del Nord-Ovest (1) · IFOM ETS - The AIRC Institute of Molecular Oncology (1) · Mansoura University (1) · NCIC Clinical Trials Group (1) · National Cancer Institute, Naples (1) · Royal Marsden NHS Foundation Trust (1) · SWOG Cancer Research Network (1)
France (6) · Italy (6) · United Kingdom (6) · United States (6) · Belgium (4) · Canada (4) · Germany (4) · South Korea (4) · Spain (4) · Australia (3) · Greece (3) · Japan (3) · Mexico (3) · Netherlands (3) · Romania (3)
Afsaneh Barzi, MD (1) · Alfredo Carrato, MD, PhD (1) · Benoist Chibaudel, MD (1) · Carla Van Herpen (1) · Chiara Cremolini, MD, PhD (1) · Clara Montagut (1) · Dion Morton, MD (1) · Hans Langendijk (1) · John Waldron, MD (1) · Lillian L. Siu, MD, FRCPC (1) · Matthew T. Seymour, MA, MD, FRCP (1)
PMID 26049686, PMID 29627309, PMID 22070868, PMID 30679026, PMID 31378656, PMID 18316791, PMID 23594787, PMID 23625191, PMID 23725851, PMID 23953030, PMID 25633805, PMID 25943574, PMID 26141683, PMID 26341920, PMID 26867820, PMID 27085587, PMID 27843597, PMID 27930762, PMID 28237539, PMID 28449055, PMID 30018814, PMID 30019318, PMID 30614531, PMID 31515083, PMID 31902066, PMID 31959339, PMID 32605298, PMID 33199443, PMID 34213592, PMID 34510716, PMID 35027324, PMID 35522139, PMID 35666229, PMID 36606664, PMID 36657089, PMID 36822922, PMID 37071094, PMID 37329889, PMID 37596461, PMID 37947140, PMID 38038829, PMID 38347302, PMID 39570583, PMID 39752885, PMID 41505697
2009 (2), 2023 (1), P30CA014089 (1), U10CA180820 (1), U10CA180888 (1)